Summary & Overview
HCPCS Level II J9258: Paclitaxel Protein-Bound Particles (Teva) Injection, 1 mg
HCPCS Level II code J9258 denotes a milligram-based injectable formulation of paclitaxel protein-bound particles (Teva), specified as not therapeutically equivalent to J9264. This code is used to bill for administration of a nanotechnology-based paclitaxel product in chemotherapy settings and is relevant to oncology practices, hospital outpatient departments, and infusion centers across the country. Nationally, precise coding for branded versus non-equivalent formulations affects coverage determinations, medical record documentation, and billing consistency for high-cost oncologic agents. Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of what the code represents, payer coverage landscape, and clinical context for use in chemotherapy infusion settings. The publication outlines common billing modifiers and administrative considerations, presents benchmark and reimbursement context where available, and summarizes policy updates that influence coverage of distinct paclitaxel formulations. The content is intended to help coding staff, practice managers, and revenue cycle professionals understand the billing tag, expected sites of service, and areas where documentation should align with payer requirements. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9258 represents an injection of paclitaxel protein-bound particles (Teva), billed per milligram with the description indicating it is not therapeutically equivalent to J9264, at a unit of 1 mg. The service type is chemotherapy drug administration delivered as an injectable oncologic agent. The typical site of service is an outpatient infusion center or hospital outpatient department where intravenous chemotherapy is administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor (commonly metastatic breast, non-small cell lung, or ovarian carcinoma) scheduled to receive paclitaxel protein-bound particles (albumin-bound paclitaxel, nab‑paclitaxel) as systemic chemotherapy. The drug J9258 is billed per milligram and is prepared by pharmacy as a sterile injectable dose. The clinical workflow: patient presents to the outpatient infusion center or hospital outpatient department for evaluation; nursing verifies chemotherapy orders, baseline labs (CBC, CMP) and performance status are reviewed; the oncology pharmacist compounds the dose using institutional protocols; the infusion nurse administers the drug through peripheral IV or central venous access over the prescribed infusion time while monitoring for infusion reactions and toxicity; supportive medications (antiemetics, premedication if indicated) are administered per regimen; follow-up visits and labs are scheduled to assess response and toxicity. Typical sites of service are outpatient infusion centers, physician office infusion suites, and hospital outpatient departments.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when administration required substantially greater physician work (rare for a drug-only infusion; applicable if additional physician services documented). |